Compare Inovio Pharmaceuticals Inc (INO) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while YieldMax NVDA Option Income Strategy ETF trades at $13.05. The key difference: YieldMax NVDA Option Income Strategy ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | NVDY | |
|---|---|---|
Market Cap | $78.55M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $2.87 | $17.96 |
52-Week Low | $0.66 | $11.58 |
Enterprise Value | $49.56M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
NVDY trades at $13.055, up 2.55% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF generates weekly dividend income, with recent payouts ranging from $0.09 to $0.15 per share. Key financial ratios are unavailable, limiting fundamental assessment. Recent news highlights the fund's strategy of selling NVIDIA call options to fund distributions, attracting income-focused investors.
The outlook for NVDY hinges on NVIDIA's volatility, which drives option premiums and dividends. However, investors sacrifice significant upside potential in NVIDIA's stock gains. Risks include underperformance versus direct NVIDIA ownership and fee drag. The ETF suits income seekers but may disappoint those seeking capital appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
